Insmed (NASDAQ:INSM) Shares Gap Up – What’s Next?

Shares of Insmed, Inc. (NASDAQ:INSM) gapped up prior to trading on Thursday. The stock had previously closed at $96.98, but opened at $110.00. Insmed shares last traded at $110.4480, with a volume of 2,255,404 shares trading hands.

Insmed News Summary

Here are the key news stories impacting Insmed this week:

• Positive Sentiment: Third-quarter revenue rose 268.4% year over year to $524.4 million, exceeding analyst expectations of approximately $500.4 million. The result was driven by BRINSUPRI revenue of $400.1 million, up 29% sequentially, while ARIKAYCE revenue reached $124.4 million. Insmed third-quarter financial results
• Positive Sentiment: Insmed raised its 2026 revenue outlook to $1.35 billion-$1.40 billion for BRINSUPRI and $460 million-$470 million for ARIKAYCE, signaling stronger-than-expected demand and execution. The company also launched BRINSUPRI in Japan. Insmed raises 2026 revenue outlook
• Positive Sentiment: Management said the U.S. BRINSUPRI launch continues to exceed expectations. Unusually heavy options activity, including call-option purchases more than twice the typical daily volume, may also be reinforcing bullish investor sentiment. Insmed Brinsupri sales report
• Negative Sentiment: Insmed reported a third-quarter loss of $0.46 per share, worse than the roughly $0.38 consensus estimate. The company remains unprofitable, so continued valuation support depends heavily on sustained BRINSUPRI growth and successful commercialization. Insmed third-quarter earnings report

Analysts Set New Price Targets

Several equities analysts have recently commented on the stock. Bank of America restated a “buy” rating and set a $207.00 price target on shares of Insmed in a research report on Monday, October 12th. JPMorgan Chase & Co. cut their price objective on shares of Insmed from $179.00 to $175.00 and set an “overweight” rating on the stock in a research report on Monday, August 10th. BMO Capital Markets reiterated an “outperform” rating on shares of Insmed in a research report on Tuesday, October 6th. Wolfe Research lowered shares of Insmed from an “outperform” rating to a “peer perform” rating in a research note on Monday, October 12th. Finally, Evercore restated an “outperform” rating and issued a $170.00 target price on shares of Insmed in a research report on Friday, August 7th. One research analyst has rated the stock with a Strong Buy rating, twenty-two have given a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, Insmed currently has an average rating of “Moderate Buy” and a consensus target price of $196.70.

Insmed Trading Up 0.9%

The business’s 50 day moving average price is $112.66 and its two-hundred day moving average price is $125.69. The company has a debt-to-equity ratio of 0.74, a quick ratio of 3.40 and a current ratio of 3.72. The company has a market capitalization of $24.59 billion, a price-to-earnings ratio of -39.92 and a beta of 0.83.

Insmed (NASDAQ:INSM) last posted its quarterly earnings data on Thursday, October 29th. The biopharmaceutical company reported ($0.46) EPS for the quarter, missing analysts’ consensus estimates of ($0.38) by ($0.08). Insmed had a negative net margin of 39.85% and a negative return on equity of 96.13%. The company had revenue of $524.43 million for the quarter, compared to analyst estimates of $500.36 million. During the same quarter in the prior year, the business earned ($1.75) EPS. Insmed’s revenue was up 268.4% compared to the same quarter last year. Equities analysts forecast that Insmed, Inc. will post -1.60 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Insmed news, Director David Brennan sold 25,000 shares of the stock in a transaction on Wednesday, September 9th. The stock was sold at an average price of $124.00, for a total transaction of $3,100,000.00. Following the completion of the transaction, the director directly owned 39,238 shares of the company’s stock, valued at approximately $4,865,512. This trade represents a 38.92% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, COO Roger Adsett sold 239,850 shares of Insmed stock in a transaction on Monday, August 10th. The shares were sold at an average price of $133.27, for a total value of $31,964,809.50. Following the transaction, the chief operating officer owned 98,744 shares in the company, valued at approximately $13,159,612.88. This trade represents a 70.84% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Company insiders own 2.10% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the company. Chicago Partners Investment Group LLC increased its position in shares of Insmed by 446.2% in the third quarter. Chicago Partners Investment Group LLC now owns 12,432 shares of the biopharmaceutical company’s stock worth $1,161,000 after acquiring an additional 10,156 shares in the last quarter. Rakuten Investment Management Inc. lifted its position in shares of Insmed by 13.5% in the 3rd quarter. Rakuten Investment Management Inc. now owns 13,741 shares of the biopharmaceutical company’s stock valued at $1,589,000 after acquiring an additional 1,632 shares in the last quarter. Provenance Wealth Advisors LLC acquired a new position in Insmed in the 3rd quarter worth approximately $366,000. Sumitomo Mitsui Trust Group Inc. boosted its stake in Insmed by 4.0% in the 3rd quarter. Sumitomo Mitsui Trust Group Inc. now owns 455,298 shares of the biopharmaceutical company’s stock worth $51,968,000 after purchasing an additional 17,585 shares during the period. Finally, Mirae Asset Global Investments Co. Ltd. purchased a new position in Insmed during the 3rd quarter worth approximately $3,983,000.

About Insmed

Insmed Incorporated is a global biopharmaceutical company focused on developing and commercializing therapies for serious and rare diseases. The company concentrates on conditions with significant unmet medical needs, particularly in pulmonary and infectious diseases.

Insmed’s lead commercial product is ARIKAYCE (amikacin liposome inhalation suspension), an inhaled antibacterial therapy used in the United States for adults with refractory Mycobacterium avium complex lung disease as part of a combination antibacterial regimen.